{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
megestrol acetate
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levonantradol is a synthetic cannabinoid analogue of delta (9)-tetrahydrocannabinol (delta(9)-THC) administered intramuscularly. It has antiemetic and anti-analgesic properties. Although its precise mechanism of action is unknown, levonantradol appears to bind and activate the cannabinoid receptors CB1 and/or CB2. Antiemetic effect of levonantradol significantly superior to chlorpromazine. However, its adverse central effects limit its utility. The main adverse events are drowsiness and dizziness. Levonantradol, administered intramuscularly to the patients suffering from postoperative pain, manifested significant analgesic efficacy. Analgesia persisted for more than 6 h with the 2.5 and 3 mg doses of levonantradol. Drowsiness was frequent but few other psychoactive effects were reported.
Class (Stereo):
CHEMICAL (ACHIRAL)
BROTIANIDE is salicylanilide derivative used to treat fascioliasis in sheep. A dose of 7 mg/kg of brotianide shows 91-99% activity against 7-14 weeks old flukes; however, its activity against 6 weeks old flukes is weak (50-90%). It also possesses 85-90% activity against paramphistomes in sheep and cattle. The maximum tolerated dose of brotianide is 27 mg/kg in sheep.
Class (Stereo):
CHEMICAL (EPIMERIC)
Tropodifene (Tropaphen) is an α-Adrenergic receptor blocking agent. Clinical trials have shown that tropaphen has a beneficial effect on hypertension. Tropaphen has a very marked adrenolytic and vasodilator action. It greatly lowers the tone of the peripheral vessels. The preparation is effective starting with a dose of 0.1 mg/kg. After injection of the drug in a dose of 0.25 mg/kg, a considerable and gradually progressive decrease in the perfusion pressure takes place. The pressure falls by 30-35% and remained at a low level for 90-100 min. With a dose of tropaphen of 0.5 mg/kg, the perfusion pressure falls by 40-45% and remains low for 120 min or more. Strong vasodilatation is also observed after injection of tropaphen into intact rabbits.
Status:
Investigational
Source:
INN:pendecamaine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Pendecamaine, a zwitterionic agent that was used as an ampholytic surface-active agent in surgical scrubs and in cosmetic and toilet preparations. Information about the current use of this drug is not available.
Status:
Investigational
Source:
NCT00002462: Phase 3 Interventional Active, not recruiting Lymphoma
(1989)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:metescufylline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:hydroxindasate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Hydroxindasate is a 5-hydroxytryptamine receptor antagonist.
Class (Stereo):
CHEMICAL (ACHIRAL)
Aclantate is a nonsteroidal anti-inflammatory drug.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Licofelone (ML 3000) is a pyrrolizine derivative originally discovered by Merckle GmbH and developed by EuroAllaince with a unique pharmacological profile, which comprises optimal gastrointestinal tolerability and high analgesic and anti-inflammatory activity. These effects are due to balanced and selective inhibition of both cyclo-oxygenase and 5-lipoxygenase. Inhibition of 5-lipoxygenase may reduce the gastrointestinal toxicity associated with other non steroidal anti-inflammatory drugs, which only inhibit cyclooxygenase. Licofelone also has antipyretic and antiaggregatory properties. Clinical and preclinical trials were also undertaken for osteoarthritis, rheumatoid arthritis, asthma, pain and inflammation. However, development for these indications appear to have been discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Gemopatrilat is a vasopeptidase inhibitor, that was found to inhibit plasma and renal angiotensin converting enzyme (ACE), as well as renal neutral endopeptidase (NEP). Gemopatrilat is rapidly absorbed, and causes inhibition of circulating and renal ACE and renal NEP after a single oral dose for up to 48 hours in rats. Potentially, this is because the free sulfhydryl group of gemopatrilat forms reversible disulfide linkages with plasma and tissue proteins and is thus eliminated from the body at a very slow rate. Similar metabolism of the compound was found in rat, dog, and human. Gemopatrilat was evaluated for its potential in treatment of antihypertensive activity in hypertension (independent of age, renin and salt status or ethnic origin), as well as its potential as a new therapeutic modality for the treatment of congestive heart failure. The drug was never marketed. A phase II study for treatment of hypertension and heart failure has been discontinued.
